RO7656594

Phase 1Small molecule

Roche

RO7656594 is one of 3 small molecule programs targeting Advanced Prostate Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Prostate CancerRecruiting

Advanced Prostate CancerPhase 1

Recruiting

Competition

Competitive Landscape

4 competitors in Advanced Prostate Cancer

#DrugCompanyPhaseTrials

XNW5004

EEvopoint Biosciences Inc.

Phase 2

1 2

HRS-5041

JJiangsu HengRui Medicine Co., Ltd.

Phase 1

1 3

RO7656594

Roche

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Advanced Prostate Cancer

NCT05800665

Clinical

Trials by Indication[1]

Advanced Prostate Cancer1 trial

A Phase 1, Open-Label, Multicenter, Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients With Advanced or Metastatic Prostate Cancer

Recruiting· Roche logo

Roche·Phase 1·NCT05800665·210 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RO7656594. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RO7656594 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RO7656594. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Roche

RO7656594

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Advanced Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News